Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2023 | Using SBRT to delay systemic therapy for patients with oligometastatic RCC

Shankar Siva • 17 Feb 2023
GU Cancers 2023
Genitourinary Cancer Kidney Cancer

Shankar Siva, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses several recent trials whose results supported the use of stereotactic body radiotherapy (SBRT) to delay systemic therapy for patients with low-volume recurrent kidney cancer. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Shankar Siva

How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Long-term results from FASTRACK II: SABR for primary kidney cancer
2:15
Long-term results from FASTRACK II: SABR for primary kidney cancer
Shankar Siva • 16 May 2026
The importance of radiation dose and quality in improving outcomes for patients with NSCLC
1:03
The importance of radiation dose and quality in improving outcomes for patients with NSCLC
Shankar Siva • 31 May 2025

Related Videos

Real-world outcomes highlight unmet needs in R/R germ cell tumors
1:26
Real-world outcomes highlight unmet needs in R/R germ cell tumors
Darren Feldman • 24 Oct 2026
The future of targeting claudin-6 in relapsed germ cell tumors
0:52
The future of targeting claudin-6 in relapsed germ cell tumors
Darren Feldman • 24 Oct 2026
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
2:18
CATALINA-1: ixotatug vedotin, a claudin 6-targeted ADC, in germ cell tumors
Darren Feldman • 24 Oct 2026
How will EIK1003 fit in the treatment landscape of prostate cancer?
0:42
How will EIK1003 fit in the treatment landscape of prostate cancer?
Guru Sonpavde • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals